Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan 45139-56111, Iran.
Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences (ZUMS), Zanjan 45139-56111, Iran.
Iran Biomed J. 2020 Jul;24(4):229-35. doi: 10.29252/ibj.24.4.229. Epub 2020 Apr 19.
Numerous studies confirmed that significant decrease in tissue decorin (DCN) expression is associated to tumor progression and metastasis in certain types of cancer including prostate cancer (PC). However, the potential prognostic value of tissue DCN in PC has not yet been investigated.
A total number of 40 PC and 42 patients with benign prostatic hyperplasia (BPH) were investigated for the expression levels of DCN in their prostatic tissues using real-time quantitative polymerase chain reaction and immunohistochemical analyses. Urinary and plasma DCN levels were also measured by ELISA.
Despite no significant changes in the mean of urine and plasma DCN concentrations between the two study groups, tissue DCN mRNA was found to be 5.5fold lower in cancer than BPH (p = 0.0001). Similarly, the stained DCN levels appeared significantly lower in cancer patients with higher Gleason Scores (8 and 9, n = 6) than those with lower Gleason Scores (6 and 7, n = 26), with a p value of 0.049.
Here, we report, for the first time, that urine and plasma DCN does not seem to have a diagnostic value in PC, while tissue DCN could potentially be used as a prognostic marker in PC.
许多研究证实，组织中核心蛋白聚糖（DCN）的表达显著降低与某些类型的癌症（包括前列腺癌）的肿瘤进展和转移有关。然而，组织 DCN 在前列腺癌中的潜在预后价值尚未得到研究。
使用实时定量聚合酶链反应和免疫组织化学分析，对 40 例前列腺癌和 42 例前列腺增生（BPH）患者的前列腺组织中 DCN 的表达水平进行了研究。还通过 ELISA 测量了尿和血浆 DCN 水平。
尽管两组患者的尿和血浆 DCN 浓度平均值无显著变化，但癌症组织中的 DCN mRNA 水平比 BPH 低 5.5 倍（p = 0.0001）。同样，染色的 DCN 水平在具有较高 Gleason 评分（8 和 9，n = 6）的癌症患者中明显低于具有较低 Gleason 评分（6 和 7，n = 26），p 值为 0.049。
在这里，我们首次报道，尿液和血浆 DCN 似乎在前列腺癌中没有诊断价值，而组织 DCN 可能可作为前列腺癌的预后标志物。
